p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer.
about
A flexible semiparametric modeling approach for doubly censored data with an application to prostate cancer.Chromobox homolog 2 protein: A novel biomarker for predicting prognosis and Taxol sensitivity in patients with breast cancer.Tumor suppressor p53 and estrogen receptors in nuclear-mitochondrial communication.Significance of immunohistochemistry in breast cancerClassification of patients with breast cancer according to Nottingham prognostic index highlights significant differences in immunohistochemical marker expression.Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation.Polymorphisms in the DNA repair gene ERCC2/XPD and breast cancer risk: a HapMap-based case-control study among Han Women in a Chinese less-developed areaA Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers.p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53.p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905).Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term SurvivalRational Manual and Automated Scoring Thresholds for the Immunohistochemical Detection of TP53 Missense Mutations in Human Breast Carcinomas.Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial.The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis.Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).Efficacy and pharmacogenomic biomarkers in breast cancer.New insight on the biological role of p53 protein as a tumor suppressor: re-evaluation of its clinical significance in triple-negative breast cancer.Dynamic contrast-enhanced and diffusion-weighted MRI of estrogen receptor-positive invasive breast cancers: Associations between quantitative MR parameters and Ki-67 proliferation status.AGR2 oncoprotein inhibits p38 MAPK and p53 activation through a DUSP10-mediated regulatory pathway.Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse.Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer.Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer.Expression of ZNF148 in different developing stages of colorectal cancer and its prognostic value: a large Chinese study based on tissue microarray.The levels of Ki-67 positive are positively associated with lymph node metastasis in invasive ductal breast cancer.Correlation of Hormone Receptor and Human Epidermal Growth Factor Receptor-2/neu Expression in Breast Cancer with Various Clinicopathologic Factors.Tumour 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes.Successful endocrine therapy for locally advanced mucinous carcinoma of the breast.Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer.
P2860
Q30658715-F956940E-BCC9-4EE4-9518-6F67595266A9Q33597544-45DFAE9F-20B3-46C7-A86C-2FDBDBAFC689Q33632616-4B50919C-F5B2-4C26-89E1-AD44F79C2D7DQ34023682-AA366B2C-2587-40C5-B7D7-AADDD4CF1D18Q34042565-9392CDA3-FCE6-440B-AF81-6F2BE5F5A6D6Q34093947-69FBFF17-62B3-4584-87DF-E9B017872E43Q34284010-5899B2A7-6476-4EC2-8E33-CB2E9BDEEB45Q35049524-E6FCF49C-8CEF-477B-82A1-6E0F55C24635Q35051755-772B4D67-DA8C-47B2-B9FC-290FD276A0B6Q35125648-F135B477-3920-40DF-8DDE-E7712BEFF09FQ35146274-7092E819-1564-46DA-A6D5-F11C78D27A24Q35737504-59028DBE-4334-4E1F-B122-157F57E72268Q36474056-3D10BD0C-D37E-4559-AC59-0D4B5BBE7E7BQ36976986-500B4FD8-5F72-4A0E-99A9-13A67125DD0FQ37031974-053F8D5A-CAED-4DDD-92A3-41D7E61DD8C2Q37565213-95BC73E9-0C13-4712-94C4-D3DAD899FDA7Q37997046-DE3A489F-18AB-4842-A32B-A46FB2EF403AQ38417021-0732A63C-3CBE-43CC-A520-59F0AAB2A987Q39676450-2D41015A-2911-4F78-BBDD-B4ABE2D13513Q40143097-17FCDF2F-FCE8-4B61-A16C-48F33B9C757EQ40227777-812BBE2E-227A-4FDB-8A89-275A737E04D2Q40581595-630A5F1F-80B8-4856-A2FB-77EF9F97E9BCQ41716164-C00C7D47-BDCC-4B07-B27D-9336187AE932Q44812441-4146B9D6-A344-46AE-8410-41E586BD5FD0Q46324717-796336D2-DE77-4ED4-99D7-8B78EC8A85F5Q49879088-83EA7926-D97C-448B-A770-3C0A637AFAB4Q54316674-569B363D-D7A4-44DC-BDE3-EFAE3FD979B7Q54474330-A5D71A01-7579-4A51-8D63-7E8D09629E54Q54591190-E03D1F01-70B6-4688-A8F4-A28396FC10EB
P2860
p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
p53 protein accumulation predi ...... l in metastatic breast cancer.
@ast
p53 protein accumulation predi ...... l in metastatic breast cancer.
@en
type
label
p53 protein accumulation predi ...... l in metastatic breast cancer.
@ast
p53 protein accumulation predi ...... l in metastatic breast cancer.
@en
prefLabel
p53 protein accumulation predi ...... l in metastatic breast cancer.
@ast
p53 protein accumulation predi ...... l in metastatic breast cancer.
@en
P2093
P2860
P356
P1476
p53 protein accumulation predi ...... al in metastatic breast cancer
@en
P2093
Hiroko Yamashita
Hirotaka Iwase
Maho Hamaguchi
Mariko Nishio
Shunzo Kobayashi
Yoshitaka Fujii
Yukio Ando
Zhenhuan Zhang
P2860
P2888
P356
10.1186/BCR1536
P577
2006-01-01T00:00:00Z
P5875
P6179
1016960147